



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
<https://www.wjgnet.com>

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 90315

Title: Bridging the Gap: Predicting Brain Metastasis in Breast Cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04056477

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Professor, Deputy Director

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2023-11-29

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-12-17 02:53

Reviewer performed review: 2023-12-19 07:21

Review time: 2 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
<https://www.wjgnet.com>

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This Letter presents a better understanding about the paper by Yu-Rui Chen and Zu-Xin Xu et al. Positive HER2 status, absence of estrogen receptor expression, and the presence of liver metastasis emerge as pivotal risk factors in the context of breast cancer brain metastasis. The routine incorporation of MRI, exploration of genetic mutations linked to metastasis, and the intricate role of radiotherapy, including potential prophylactic applications, remain subjects of debate within clinical circles. A comprehensive grasp of these risk factors necessitates a collaborative approach across multiple disciplines, facilitating precision in the administration of local treatments and targeted therapies, notably in cases of HER2+ tumors. This collaborative strategy directly correlates with prolonged survival outcomes. The letter can be accepted in the current form.